- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00772694
Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy (GCT)
Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy
Germ cell tumors, a relatively rare disease, but most common malignancy in young males, occur most frequently in testis. The incidence is about 1%, but is increasing in the majority of developed countries. The testicular cancer is an extremely important oncological condition due to his high rate of 80-90% of curability, which can be achieved by combination of chemotherapy and surgery.
Some of 20-30% of patients will experience disease progression after first line cisplatin-based chemotherapy and salvage 2nd line conventional-dose cisplatin-based salvage chemotherapy will result in long term remissions in < 50% of patients (VeIP - vinblastine, ifosfamide, cisplatin, VIP/PEI - ifosfamide, etoposide, cisplatin, TIP - paclitaxel, ifosfamide, cisplatin). In multiple relapsed patients the 3rd line chemotherapy can induce remission in up to 40% (gemcitabine, oxaliplatin), 23% RR (TG - paclitaxel, gemcitabine), 20% CR (IPO - irinotecan, paclitaxel, oxaliplatin), but only small proportion of them can be cured, usually with subsequent consolidation surgery. At that stage the disease is usually chemorefractory and there are no other chemotherapy regimens of proven benefit (7).
The purpose of this study is to determine if multiple-relapsed chemorefractory pts may benefit from sorafenib monotherapy.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Iwona A Skoneczna, MD
- Phone Number: +48225462098
- Email: i.skoneczna@coi.waw.pl
Study Contact Backup
- Name: Agnieszka Chaladaj-Kujawska, MD
- Phone Number: +48225462057
Study Locations
-
-
-
Warsaw, Poland, 02781
- Recruiting
- Chemotherapy Unit, Dept of Urology, Instituite of Oncology
-
Principal Investigator:
- Iwona A Skoneczna, MD
-
Sub-Investigator:
- Agnieszka Chaladaj-Kujawska, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients > 18 years of age
- Patients with histologically proven germ cell neoplasm (gonadal or extragonadal primary)
- Patients must have the disease not amendable to cure with either surgery or chemotherapy
- Patients must have failed at least two cisplatin-based combination chemotherapy regimens.
Failure on prior regimens will be defined as either:
- A ≥ 25% increase in sum of target lesions, new lesions, or
- An increasing AFP or HCG above the nadir level.
- Patients with at least one measurable lesion by CT scan or MRI according to RECIST criteria
- Adequate bone marrow, liver and renal function, assessed no longer than 14 days before treatment start, defined by the following laboratory test limits: WBC > 2.0 x 109/l and platelets > 60 x 109/l, total bilirubin < 2 x upper limit, AST and ALT < 5 x upper limit normal, serum creatinine < 2 x UNL
- WHO Performance Status 0, 1, 2
- No concurrent chemotherapy or radiotherapy
- Life expectancy of at least 12 weeks
- Absence of any physiological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
- A signed informed consent must be obtained prior to any study specific procedures
- All patients must agree to use adequate contraception during the whole study period
Exclusion Criteria:
- Patients not fulfilling of inclusion criteria
- Primary radiotherapy in the field of target lesion
- Major surgery (RPLND) within 4 weeks before the start of study drug or concurrent serious non-healing wounds, ulcers or bone fractures.
- Known serious and active bacterial, viral or fungal infection (> grade II CTC-AE) including HBV, HCV and HIV carrier state.
- Previous or concurrent malignancy except for basal cell carcinoma of the skin
- Uncontrolled hypertension.
- Thrombotic or embolic event in last 6 months prior to inclusion.
- Impairment of gastrointestinal tract, or GI disease that may influence the bioavailability of oral sorafenib
- Substance and alcohol abuse (nicotine use is allowed)
- Known or suspected hypersensitivity to sorafenib.
- Participants in any other clinical trial using investigational drug within 4 weeks prior to study entry
- Prior use of investigational or licensed angiogenesis and RAF kinase or MEK inhibitors.
- Patient unwilling or unable to give informed consent
- Any condition that may in the investigator's opinion jeopardize the safety of the patient or his compliance in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: sorafenib
drug
|
tablets 200mg, 400mg bid continuously in 4-week cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival
Time Frame: one year
|
one year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ORR Evaluation of the usefulness the CT with vasculature visualisation option in the measurement of the objective response Evaluation of quality of life
Time Frame: one year
|
one year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Gonadal Disorders
- Endocrine Gland Neoplasms
- Genital Neoplasms, Male
- Testicular Diseases
- Testicular Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Sorafenib
Other Study ID Numbers
- 12602
- PL/ 183/UR/CEBK/04/08
- EudraCT 2007-007599-40
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Testicular Cancer
-
Haukeland University HospitalKarolinska University Hospital; Oslo University Hospital; University Hospital... and other collaboratorsRecruitingSeminoma | Testicular Germ Cell Cancer | Non-Seminoma Testicular Cancer | Stage I Testicular Cancer | Stage II Testicular Cancer | Stage III Testicular Cancer | Stage IV Testicular Cancer | Relapse Testicular CancerNorway, Sweden
-
University Medical Center GroningenDutch Cancer SocietyCompletedNon-seminomatous Testicular CancerNetherlands
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)RecruitingSeminoma | Germ Cell Tumor | Metachronous Malignant Neoplasm | Stage I Testicular Cancer AJCC v8 | Stage IA Testicular Cancer AJCC v8 | Stage IB Testicular Cancer AJCC v8 | Stage IS Testicular Cancer AJCC v8Canada, United States, Guam
-
National Cancer Institute, SlovakiaCompletedTesticular CancerSlovakia
-
University of California, IrvineMemorial Sloan Kettering Cancer CenterUnknown
-
University of Texas Southwestern Medical CenterActive, not recruitingTesticular Germ Cell Tumor | Testicular Neoplasms | Testicular Diseases | Testis Cancer | Testicular Cancer | Germ Cell Tumor | Testicular Yolk Sac Tumor | Testicular Choriocarcinoma | Germ Cell Tumor of Testis | Germ Cell Tumor, Testicular, Childhood | Germ Cell Cancer Metastatic | Germ Cell Neoplasm of Retroperitoneum and other conditionsUnited States
-
University Medical Center GroningenDutch Cancer SocietyRecruitingTesticular CancerNetherlands
-
Radboud University Medical CenterCompletedTesticular CancerNetherlands
-
Centre Hospitalier Universitaire de NiceTerminatedTesticular CancerFrance
-
Centre Leon BerardNational Cancer Institute, FranceNot yet recruitingMetastatic Testicular CancerFrance
Clinical Trials on sorafenib
-
BayerAmgenCompleted
-
Ohio State University Comprehensive Cancer CenterBayerTerminated
-
Technical University of MunichCompleted
-
Ottawa Hospital Research InstituteBayerCompletedMetastatic Colorectal CancerCanada
-
Yiviva Inc.RecruitingAdvanced Hepatocellular CarcinomaUnited States, Taiwan, China, Hong Kong
-
National Cancer Institute (NCI)CompletedNon-Small-Cell Lung CarcinomaUnited States
-
British Columbia Cancer AgencyWithdrawnLocally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN)Canada
-
Cancer Institute and Hospital, Chinese Academy...CompletedHepatocellular Carcinoma, Radiotherapy, SorafenibChina
-
Accelerated Community Oncology Research NetworkBayerTerminatedRenal Cell CarcinomaUnited States
-
China Medical University HospitalUnknown